Friday, 16 October 2026European Markets

EQVA Stock Over 27% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of EQVA (Oslo Børs Benchmark Index_GI: EQVA.OL) rose by a staggering 27.64% in 21 sessions from kr2.75 to kr3.51 at 19:24 EST on Wednesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is dropping 0.14% to kr1,243.59, after two sequential sessions in a row of losses.

About EQVA

Eqva ASA, a knowledge-based maritime company, primarily engages in the shipbuilding business worldwide. It operates in two segments, Shipbuilding Technology and Other. The company provides newbuilding, rebuilding, and service assignments on vessels for offshore oil production, renewable energy production, fishing, and fish farming for ship owners. It delivers technology for customers within the seafood, energy, and transport sectors. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was founded in 1999 and is headquartered in Fosnavåg, Norway.

Volume

Today's last reported volume for EQVA is 39440 which is 38.55% below its average volume of 33939.

Volatility

EQVA's last week, last month's, and last quarter's current intraday variation average was a negative 1.31%, a positive 1.22%, and a positive 3.11%.

EQVA's highest amplitude of average volatility was 1.60% (last week), 3.85% (last month), and 3.11% (last quarter).

More news about EQVA (EQVA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com